In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

Cigna Group plans to limit patients’ out-of-pocket expenses for medications as the insurer faces pressure from Washington ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.

Denouncing the $557 billion industry as “horrible middlemen,” responsible for—and “rich as hell” from— America’s incomparably high prescription drug prices, Trump vowed to get rid of ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for cancer, AIDS, multiple sclerosis and other serious maladies far over the ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...